Century Therapeutics (IPSC) Operating Leases (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Operating Leases of $43.9 million for Q1 2026, down 8.06% year-over-year from $47.8 million in Q1 2025, and up 9.2% quarter-over-quarter from $40.2 million in Q4 2025.
Century Therapeutics (IPSC) Operating Leases (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Operating Leases for 7 consecutive years, with $43.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 8.06% year-over-year to $43.9 million; the TTM figure through Mar 2026 stood at $43.9 million (down 8.06% YoY), while the FY2025 annual figure was $40.2 million, down 17.81% from the prior year.
- Operating Leases climbed to $43.9 million in Q1 2026 per IPSC's latest filing, from $40.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $52.7 million in Q2 2024 and bottomed at $14.4 million in Q1 2022.
- Historically, Operating Leases has averaged $41.8 million across 5 years, with a median of $43.9 million in 2026.
- Annual changes were most pronounced in 2023 — Operating Leases soared 185.29% — and 2025, when it decreased 18.99%.
- Century Therapeutics' Operating Leases stood at $38.7 million in 2022, then advanced by 20.57% to $46.7 million in 2023, then advanced by 4.93% to $49.0 million in 2024, then slipped by 17.81% to $40.2 million in 2025, then grew by 9.2% to $43.9 million in 2026.
- Business Quant data shows IPSC's Operating Leases at $43.9 million in Q1 2026, $40.2 million in Q4 2025, and $41.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.63 Mn |
| Mar 31, 2026 | 43.94 Mn |
| Dec 31, 2025 | 40.24 Mn |
| Sep 30, 2025 | 41.19 Mn |
| Jun 30, 2025 | 46.59 Mn |
| Mar 31, 2025 | 47.79 Mn |
| Dec 31, 2024 | 48.96 Mn |
| Sep 30, 2024 | 50.84 Mn |
| Jun 30, 2024 | 52.71 Mn |
| Mar 31, 2024 | 44.25 Mn |
| Dec 31, 2023 | 46.66 Mn |
| Sep 30, 2023 | 45.54 Mn |
| Jun 30, 2023 | 40.83 Mn |
| Mar 31, 2023 | 41.17 Mn |
| Dec 31, 2022 | 38.70 Mn |
| Sep 30, 2022 | 36.59 Mn |
| Jun 30, 2022 | 30.43 Mn |
| Mar 31, 2022 | 14.43 Mn |
| Dec 31, 2021 | 14.56 Mn |
| Sep 30, 2021 | 14.75 Mn |